Prolactin in men's health and disease

Current Opinion in Urology

Volumn 21, Issue 6, 2011, Pages 527-534

  Bolyakov, Alexander ^a,b   Paduch, Darius A ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Consulting Research Services Inc ^*  (United States)

Author keywords

dopamine agonists; hyperprolactinemia; microprolactinoma; prolactinoma

Indexed keywords

ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BROMOCRIPTINE; BUTYROPHENONE; CABERGOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; LEVOTHYROXINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OPIATE AGONIST; OPIATE ANTAGONIST; PHENOTHIAZINE; PROLACTIN; QUINAGOLIDE; RISPERIDONE; TEMOZOLOMIDE;

ALCOHOL INTOLERANCE; ANXIETY; CLINICAL EVALUATION; COLD SENSITIVITY; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG HALF LIFE; DRUG INDUCED HEADACHE; EXERCISE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GAMMA RADIATION; GLYCEMIC CONTROL; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; LACTATION; NOSE CONGESTION; OBESITY; PREGNANCY; PRIORITY JOURNAL; PROLACTINOMA; PSYCHOSIS; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; STRESS; TREATMENT RESPONSE; TUMOR VOLUME; VALVULAR HEART DISEASE; VASOSPASM;

BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MEN'S HEALTH; PITUITARY NEOPLASMS; PROGNOSIS; PROLACTIN; PROLACTINOMA; REPRODUCTION; REPRODUCTIVE HEALTH; UP-REGULATION;

EID: 80053981249     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32834bdf01     Document Type: Review

References (59)

1. McCudden CR, Sharpless JL, Grenache DG. Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. Clin Chim Acta 2010; 411:155-160.
2. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiolog Rev 2000; 80:1523-1631.
3. Bertram R, Helena CV, Gonzalez-Iglesias AE, et al. A tale of two rhythms: the emerging roles of oxytocin in rhythmic prolactin release. J Neuroendocrinol 2010; 22:778-784.
4. Morales T. Recent findings on neuroprotection against excitotoxicity in the hippocampus of female rats. J Neuroendocrinol 2011. [Epub ahead of print]. doi: 10.1111/j.1365-2826.2011.02141.x
5. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Rev 1996; 17:639-669. (Pubitemid 26425260)
6. Riddle O, Bates RW, Dykshorn SW. The preparation, identification and assay of prolactin: a hormone of the anterior pituitary. Am J Physiol 1933; 105:191-216.
7. Benker G, Jaspers C, Hausler G, Reinwein D. Control of prolactin secretion. Klinische Wochenschrift 1990; 68:1157-1167.
8. van Zaane B, Squizzato A, Reuwer AQ, et al. Prolactin and venous thrombosis: indications for a novel risk factor? Arterioscler Thromb Vasc Biol 2011; 31:672-677.
9. Mazziotti G, Porcelli T, Mormando M, et al. Vertebral fractures in males with prolactinoma. Endocrine 2011; 39:288-293.
10. van den Burg EH, Neumann ID. Bridging the gap between GPCR activation and behaviour: oxytocin and prolactin signalling in the hypothalamus. J Molec Neurosci 2011; 43:200-208.
11. Liu X, Robinson GW, Wagner KU, et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11:179-186. (Pubitemid 27081895)
12. Musey VC, Collins DC, Musey PI, et al. Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987; 316:229-234. (Pubitemid 17051047)
13. Wang DY, de Stavola BL, Bulbrook RD, et al. The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 1988; 24:1225-1231.
14. Buntin JD, Tesch D. Effects of intracranial prolactin administration on maintenance of incubation readiness, ingestive behavior, and gonadal condition in ring doves. Hormones Behav 1985; 19:188-203. (Pubitemid 15049674)
15. Nag S, Sanyal S, Ghosh KK, Biswas NM. Prolactin suppression and spermatogenic developments in maturing rats. A quantitative study. Hormone Res 1981; 15:72-77. (Pubitemid 12214193)
16. Dombrowicz D, Sente B, Closset J, Hennen G. Dose-dependent effects of human prolactin on the immature hypophysectomized rat testis. Endocrinology 1992; 130:695-700.
17. Rubin RT, Poland RE, Tower BB. Prolactin-related testosterone secretion in normal adult men. J Clin Endocrinol Metab 1976; 42:112-116.
18. Gunasekar PG, Kumaran B, Govindarajulu P. Prolactin and Leydig cell steroidogenic enzymes in the bonnet monkey (Macaca radiata). Int J Androl 1988; 11:53-59. (Pubitemid 18039862)
19. Gunasekar PG, Kumaran B, Govindarajulu P. Role of prolactin on Leydig, Sertoli and germ cellular neutral lipids in bonnet monkeys, Macaca radiata. Endocrinologia Japonica 1991; 38:1-8.
20. De Rosa M, Zarrilli S, Di Sarno A, et al. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine 2003; 20:75-82. (Pubitemid 36515190)
21. El-Sakka AI, Hassoba HM, Sayed HM, Tayeb KA. Pattern of endocrinal changes in patients with sexual dysfunction. J Sex Med 2005; 2:551-558. (Pubitemid 40975840)
22. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011; 26:130-140.
23. Kars M, Souverein PC, Herings RM, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 2009; 94:2729-2734.
24. Molitch ME, Gillam MP. Lymphocytic hypophysitis. Hormone Res 2007; 68 (Suppl 5):145-150.
25. Molitch ME. Antipsychotic drug-induced hyperprolactinemia: clinical implications. Endocr Pract 2000; 6:479-481.
26. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children [review]. J Child Adolesc Psychopharmacol 2001; 11:435-440. (Pubitemid 34117293)
27. Saha MT, Saha HH, Niskanen LK, et al. Time course of serum prolactin and sex hormones following successful renal transplantation. Nephron 2002; 92:735-737. (Pubitemid 35316882)
28. Tohei A, Taya K, Watanabe G, Voogt JL. Hypothyroidism increases prolactin secretion and decreases the intromission threshold for induction of pseudopregnancy in adult female rats. Physiol Behav 2000; 69:391-397. (Pubitemid 30460075)
29. Mabini R, Wergowske G, Baker FM. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone. Psychiatr Serv 2000; 51:983-985. (Pubitemid 30613003)
30. Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 2011; 96:1633-1641.
31. Kreutzer J, Fahlbusch R. Diagnosis and treatment of pituitary tumors. Curr Opin Neurol 2004; 17:693-703. (Pubitemid 39613001)
32. Molitch ME. Pituitary adenomas. Ann Internal Med 1995; 122:476.
33. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 1994; 41:359-364. (Pubitemid 24278331)
34. Fideleff HL, Boquete HR, Sequera A, et al. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 2000; 13:261-267. (Pubitemid 30163750)
35. Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003; 148:325-331. (Pubitemid 36410718)
36. Vilar L, Freitas MC, Naves LA, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 2008; 31:436-444. (Pubitemid 352005743)
37. Martin TL, Kim M, Malarkey WB. The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 1985; 60:855-858. (Pubitemid 15085111)
38. dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011; 19:800-805.
39. Molitch ME. Pituitary tumors: cabergoline versus bromocriptine - a metaanalysis? Nat Rev Endocrinol 2011; 7:254-255.
40. Mantegani S, Brambilla E, Varasi M. Ergoline derivatives: receptor affinity and selectivity. Farmaco 1999; 54:288-296. (Pubitemid 29306634)
41. Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004; 89:1704-1711. (Pubitemid 38507923)
42. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000; 85:2247-2252. (Pubitemid 32269250)
43. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84:2518-2522.
44. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331:904-909. (Pubitemid 24299871)
45. Ferrari C, Paracchi A, Mattei AM, et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992; 126:489-494.
46. De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138:286-293. (Pubitemid 28154778)
47. De Rosa M, Zarrilli S, Vitale G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89:621-625. (Pubitemid 38269868)
48. Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001; 86:5256-5261. (Pubitemid 33070245)
49. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60:698-705. (Pubitemid 15147556)
50. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46. (Pubitemid 46041752)
51. Mann WA. Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. Eur J Clin Invest 2011; 41:334-342.
52. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006; 65:265-273. (Pubitemid 44079693)
53. Kars M, Pereira AM, Smit JW, Romijn JA. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 2009; 20:387-393.
54. Liu JK, Couldwell WT. Contemporary management of prolactinomas. Neurosurg Focus 2004; 16:E2.
55. Castinetti F, Regis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 2010; 6:214-223.
56. Santoro A, Minniti G, Ruggeri A, et al. Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results. Surg Neurol 2007; 68:513-518; discussion 518. (Pubitemid 47610688)
57. Qu X, Wang M, Wang G, et al. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol 2011; 164:499-504.
58. Sun DQ, Cheng JJ, Frazier JL, et al. Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev 2010; 34:181-189.
59. Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 2010; 163:843-851.